company background image
PTX

Prescient Therapeutics ASX:PTX Stock Report

Last Price

AU$0.15

Market Cap

AU$106.3m

7D

19.2%

1Y

-32.6%

Updated

30 Jun, 2022

Data

Company Financials
PTX fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

PTX Stock Overview

Prescient Therapeutics Limited, a clinical stage oncology company, develops novel drugs for the treatment of various cancers in Australia.

Prescient Therapeutics Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Prescient Therapeutics
Historical stock prices
Current Share PriceAU$0.15
52 Week HighAU$0.30
52 Week LowAU$0.12
Beta0.98
1 Month Change-8.82%
3 Month Change0%
1 Year Change-32.61%
3 Year Change260.47%
5 Year Change192.45%
Change since IPO-99.78%

Recent News & Updates

Jun 19
Prescient Therapeutics (ASX:PTX) Is In A Strong Position To Grow Its Business

Prescient Therapeutics (ASX:PTX) Is In A Strong Position To Grow Its Business

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...

Feb 27
Prescient Therapeutics (ASX:PTX) Is In A Strong Position To Grow Its Business

Prescient Therapeutics (ASX:PTX) Is In A Strong Position To Grow Its Business

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

Shareholder Returns

PTXAU BiotechsAU Market
7D19.2%1.2%2.8%
1Y-32.6%-8.4%-9.6%

Return vs Industry: PTX underperformed the Australian Biotechs industry which returned -8.4% over the past year.

Return vs Market: PTX underperformed the Australian Market which returned -9.6% over the past year.

Price Volatility

Is PTX's price volatile compared to industry and market?
PTX volatility
PTX Average Weekly Movement16.3%
Biotechs Industry Average Movement10.1%
Market Average Movement9.8%
10% most volatile stocks in AU Market16.7%
10% least volatile stocks in AU Market4.3%

Stable Share Price: PTX is more volatile than 75% of Australian stocks over the past 3 months, typically moving +/- 16% a week.

Volatility Over Time: PTX's weekly volatility (16%) has been stable over the past year, but is still higher than 75% of Australian stocks.

About the Company

FoundedEmployeesCEOWebsite
1986n/aSteven Yatomi-Clarkehttps://ptxtherapeutics.com

Prescient Therapeutics Limited, a clinical stage oncology company, develops novel drugs for the treatment of various cancers in Australia. Its lead drug candidate is PTX-200, which is in Phase II clinical trial for HER2-negative breast cancer, Phase IB/2 clinical trial in relapsed and refractory AML, and Phase 1b in recurrent or persistent platinum-resistant ovarian cancer; and PTX-100, a RhoA inhibitor, for hematological and solid malignancies that focuses on cancers with Ras and RhoA mutations. Prescient Therapeutics Limited has a collaboration agreement with Carina Biotech to develop cell therapies.

Prescient Therapeutics Fundamentals Summary

How do Prescient Therapeutics's earnings and revenue compare to its market cap?
PTX fundamental statistics
Market CapAU$106.33m
Earnings (TTM)-AU$4.97m
Revenue (TTM)AU$1.38m

73.8x

P/S Ratio

-20.4x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
PTX income statement (TTM)
RevenueAU$1.38m
Cost of RevenueAU$0
Gross ProfitAU$1.38m
Other ExpensesAU$6.35m
Earnings-AU$4.97m

Last Reported Earnings

Dec 31, 2021

Next Earnings Date

n/a

Earnings per share (EPS)-0.0076
Gross Margin100.00%
Net Profit Margin-359.85%
Debt/Equity Ratio0.0%

How did PTX perform over the long term?

See historical performance and comparison
We’ve recently updated our valuation analysis.

Valuation

Is PTX undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • PEG Ratio

Key Valuation Metric

Which metric is best to use when looking at relative valuation for PTX?

Other financial metrics that can be useful for relative valuation.

PTX key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue66.3x
Enterprise Value/EBITDA-18x
PEG Ration/a

Price to Book Ratio vs Peers

How does PTX's PB Ratio compare to its peers?

PTX PB Ratio vs Peers
The above table shows the PB ratio for PTX vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPBEstimated GrowthMarket Cap
Peer Average3.4x
ACW Actinogen Medical
3.7x-16.7%AU$84.4m
OCC Orthocell
5.6xn/aAU$78.9m
CHM Chimeric Therapeutics
2.2x-11.6%AU$40.0m
IMM Immutep
2.3x56.1%AU$252.0m
PTX Prescient Therapeutics
5.4xn/aAU$106.3m

Price-To-Book vs Peers: PTX is expensive based on its Price-To-Book Ratio (5.4x) compared to the peer average (3.4x).


Price to Earnings Ratio vs Industry

How does PTX's PE Ratio compare vs other companies in the AU Biotechs Industry?

Price-To-Book vs Industry: PTX is expensive based on its Price-To-Book Ratio (5.4x) compared to the Australian Biotechs industry average (2.5x)


Price to Book Ratio vs Fair Ratio

What is PTX's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

PTX PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio5.4x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate PTX's Price-To-Book Fair Ratio for valuation analysis.


Share Price vs Fair Value

What is the Fair Price of PTX when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate PTX's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate PTX's fair value for valuation analysis.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate PTX's PEG Ratio to determine if it is good value.


Discover undervalued companies

Future Growth

How is Prescient Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

Future Growth Score

0/6

Future Growth Score 0/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


15.7%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Prescient Therapeutics has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Discover growth companies

  • Examine Prescient Therapeutics's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
  • Prescient Therapeutics competitive advantages and company strategy can generally be found in its financial reports archived here.

Past Performance

How has Prescient Therapeutics performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


-13.2%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: PTX is currently unprofitable.

Growing Profit Margin: PTX is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: PTX is unprofitable, and losses have increased over the past 5 years at a rate of 13.2% per year.

Accelerating Growth: Unable to compare PTX's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: PTX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (8.2%).


Return on Equity

High ROE: PTX has a negative Return on Equity (-26.66%), as it is currently unprofitable.


Discover strong past performing companies

Financial Health

How is Prescient Therapeutics's financial position?

Financial Health Score

6/6

Financial Health Score 6/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: PTX's short term assets (A$15.7M) exceed its short term liabilities (A$390.1K).

Long Term Liabilities: PTX's short term assets (A$15.7M) exceed its long term liabilities (A$41.1K).


Debt to Equity History and Analysis

Debt Level: PTX is debt free.

Reducing Debt: PTX had no debt 5 years ago.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: PTX has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: PTX has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of 9.3% each year


Discover healthy companies

Dividend

What is Prescient Therapeutics's current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate PTX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate PTX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if PTX's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if PTX's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as PTX has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

5.0yrs

Average management tenure


CEO

Steven Yatomi-Clarke

6.25yrs

Tenure

AU$799,945

Compensation

Mr. Steven Lee Yatomi-Clarke has been Chief Executive Officer and Managing Director of Prescient Therapeutics Limited since February 15, 2016. Mr. Yatomi-Clarke has been Director of Prescient Therapeutics...


CEO Compensation Analysis

Compensation vs Market: Steven's total compensation ($USD549.94K) is above average for companies of similar size in the Australian market ($USD287.52K).

Compensation vs Earnings: Steven's compensation has increased whilst the company is unprofitable.


Leadership Team

Experienced Management: PTX's management team is considered experienced (5 years average tenure).


Board Members

Experienced Board: PTX's board of directors are considered experienced (7.1 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 2.2%.


Top Shareholders

Company Information

Prescient Therapeutics Limited's employee growth, exchange listings and data sources


Key Information

  • Name: Prescient Therapeutics Limited
  • Ticker: PTX
  • Exchange: ASX
  • Founded: 1986
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: AU$106.327m
  • Shares outstanding: 654.32m
  • Website: https://ptxtherapeutics.com

Location

  • Prescient Therapeutics Limited
  • 100 Albert Road
  • Level 4
  • Melbourne
  • Victoria
  • 3205
  • Australia

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/06/30 00:00
End of Day Share Price2022/06/30 00:00
Earnings2021/12/31
Annual Earnings2021/06/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.